COMMUNIQUÉS West-GlobeNewswire

ABLi Therapeutics to Present at the Citizens Life Sciences Conference
05/03/2026
ATLANTA and BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- ABLi Therapeutics (“ABLi”), a biotechnology company developing therapeutics to address diseases that arise from activation of Abelson Tyrosine Kinases (c-Abl [...]
New Survey Reveals Over Half of Americans Delayed Healthcare in Past Year, Citing Cost and Schedule Conflicts as Primary Barriers
05/03/2026
Data shows significant “Health Debt” accumulating among working-age adults, with Millennials and Gen X facing unique pressures that drive them away from preventive care MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- A [...]
Starton Therapeutics Files Patent Applications for the Use of CAR-T Cell Therapies in Combination with its Proprietary, Continuous Low-Dose Immunomodulatory Therapy, STAR-LLD, a formulation of Lenalidomide, for the Treatment of Blood Cancer
05/03/2026
The potential of STAR-LLD to improve lenalidomide’s therapeutic index suggests an opportunity for use in combination with CAR-T cell therapies. As described in the patent application, STAR-LLD's improved therapeutic [...]
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
05/03/2026
WEST CHESTER, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases [...]
Texas Original Opens Five New Locations to Expand Medical Marijuana Access Across the State
05/03/2026
Two satellite locations and three pickup sites bring life-changing medicine closer to patients and provide more flexibility BASTROP, Texas, March 05, 2026 (GLOBE NEWSWIRE) -- Texas Original , the state’s leading medical [...]
Kestrel Therapeutics Announces IND Clearance by U.S. FDA of KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, Enabling Initiation of Phase 1 Trial
05/03/2026
WATERTOWN, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Kestrel Therapeutics Inc. (“Kestrel” or the “Company”), a clinical stage biotechnology company developing next-generation small-molecule inhibitors targeting mutant [...]
Silexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General Meeting
05/03/2026
Grand Cayman, Cayman Island, March 05, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, reminds its shareholders of the [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
05/03/2026
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 5 MARCH 2026 at 15.00 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
Tangram Therapeutics Announces First Participant Dosed in Phase 1/2 RESTORE-MASH Trial of TGM-312, a Novel Investigational RNAi Medicine
05/03/2026
Phase 1/2 RESTORE-MASH trial will evaluate safety, pharmacokinetics, and pharmacodynamics of TGM-312 in healthy volunteers and MASH patients Initial data anticipated H2 2026 LONDON, March 05, 2026 (GLOBE NEWSWIRE) -- [...]
Curanex Forms World Class Scientific Advisory Board
05/03/2026
Board Includes Former Fortune 100 Pharma Executive and Leading US Medical Research Academic Jericho, New York, March 05, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company [...]
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
05/03/2026
SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class [...]
Collegium to Present New Real-World Data at PainConnect 2026
05/03/2026
STOUGHTON, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present two posters featuring real-world data from its portfolio of differentiated pain [...]
BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026
05/03/2026
Company to engage industry partners and distribution channels as part of expanding BioCosmeceutical commercialization strategy MELVILLE, N.Y., March 05, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“ [...]
Galimedix Therapeutics to present promising pre-clinical data with next generation oral amyloid beta aggregation modulator at AD/PD™ 2026 Conference
05/03/2026
Kensington, MD, USA and Munich/Martinsried, Germany, March 05, 2026 (GLOBE NEWSWIRE) -- Galimedix Therapeutics to present promising pre-clinical data with next generation oral amyloid beta aggregation modulator at AD/PD [...]
Avalyn Appoints Biopharmaceutical Industry Leader Kate Haviland to Board of Directors
05/03/2026
Appointment adds extensive commercial, operational, and strategic leadership experience as Avalyn advances its pipeline of inhaled therapies for pulmonary fibrosis BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- Avalyn [...]
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
05/03/2026
In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified event threshold of 80% overall survival (OS) events was reached in Q1 2026; [...]
CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
05/03/2026
‒ Q4 2025 Net Revenue of $128.6 million ‒ ‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒ ‒ Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ‒ ‒ Conference Call Scheduled for Today at 8: [...]
CervoMed to Participate in Upcoming Investor Conferences
05/03/2026
BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that Company management will [...]
Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort
05/03/2026
The Company is expected to finalize the Clinical Study Report (CSR) in Q2 2026 to support planned end of Phase 2 (EOP2) meeting with the FDA PHILADELPHIA, March 05, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: [...]

Pages